Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
188
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas

Luis MalpicaDivision of Hematology-Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; ORCID Iconhttp://orcid.org/0000-0002-7082-1846
ORCID Icon,
Bolanle MufukaDepartment of Internal Medicine, University of North Carolina, Chapel Hill, NC, USA;
,
Jonathan GaleottiDepartment of Pathology, University of North Carolina, Chapel Hill, NC, USA;
,
Xianming TanDepartment of Biostatistics Shared Resource, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA;
,
Natalie GroverDivision of Hematology-Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA;
,
Stephen M. ClarkDepartment of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
,
Anne BeavenDivision of Hematology-Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA;
,
Hyman MussDivision of Hematology-Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA;
&
Christopher DittusDivision of Hematology-Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-9794-7908
ORCID Icon show all
Pages 1508-1511 | Received 24 Oct 2019, Accepted 25 Jan 2020, Published online: 09 Feb 2020

References

  • Rovira J, Valera A, Colomo L, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015;94(5):803–812.
  • Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116(24):5103–5110.
  • Lakshmaiah KC, Asati V, Babu KG, et al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2018;100(6):644–648.
  • Cui Y, Li X, Sun Z, et al. Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(9):2613–2618.
  • Hyman CS. Prednisone therapy of acute lymphatic leukemia in children. Cancer. 1956;9(5):965–970.
  • Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–641.
  • Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
  • Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116.
  • Pfreundschuh M, Poeschel V, Zeynalova S, et al. Optimization of rituximab for the treatment of diffuse large b-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;32(36):4127–4133.
  • Peyrade F, Serge B, Delwail V, et al. Pre-phase chemotherapy followed by ofatumumab (OFA) and reduced dose CHOP (OFA-mini-CHOP) for patients over 80 years with diffuse large B-cell lymphoma (DLBCL) – a lymphoma study association (LYSA) prospective phase II study (LNH09-7B). Blood. 2014;124(21):3042–3042.
  • Li Y, Klippel Z, Shih X, et al. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer. 2016;24(10):4377–4383.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.